Adagene Begins Phase 1 Trial Of Muzastotug Plus INCA33890 In MSS Colorectal Cancer; Stock Up

Adagene (ADAG) dosed the first patient in a Phase 1 trial of muzastotug with Incyte's (INCY) INCA33890 for MSS colorectal cancer. The open-label study targets third-line patients. ADAG shares rose 10.47% in pre-market trading to $2.85. The 52-week range is $1.30 to $4.85.

Original reporting
Published Oct 28, 2026, 12:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ADAG
Bullish
high confidence
Mentioned
$ADAG
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ADAGBullishLow
01

Why it matters

The dosing of the first patient signals that the collaboration with Incyte is progressing on schedule, which can reduce execution risk and attract speculative buying.

02

Market read

The announcement moved ADAG shares up ~10% pre‑market, indicating immediate market relevance for traders.

03

What to watch

The partnership with Incyte may provide additional resources but also dilutes Adagene's upside if Incyte takes a larger share of future revenues.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Adagene (ADAG) is a clinical‑stage biotech focused on immuno‑oncology. The Phase 1 study targets microsatellite stable colorectal cancer, a hard‑to‑treat indication.

Company-level read

Ticker impact

$ADAGBullishHigh confidence
Context

Adagene announced the first patient dosed in a Phase 1 trial of its drug muzastotug combined with Incyte's INCA33890 for MSS colorectal cancer.

Expected impact

likely upward pressure as the market prices in the early‑stage trial progress

Evidence & confidence

First‑patient dosing is fresh, material news for a micro‑cap biotech and has already moved the stock up ~10% in pre‑market trading.

Market effects

Early‑stage oncology trial activity may boost interest in the MSS colorectal cancer therapeutic niche.

Primarily U.S. biotech investors; limited broader market effect.

Minimal outside the biotech sector.

Counterpoint

If the trial encounters safety issues, the initial hype could reverse quickly.

Key entities

  • Adagene Inc.

    US‑listed biotech developing the anti‑CTLA‑4 SAFEbody muzastotug.

  • Incyte Corp.

    Partner sponsoring the trial and providing INCA33890.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.